Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)

PHASE4TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

November 17, 2023

Study Completion Date

December 31, 2024

Conditions
Dry Eye
Interventions
DRUG

Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)

Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.

OTHER

ProLong™ collagen plugs

The long term synthetic punctal plug is composed of an absorbable copolymer material and measures 0.4mm in diameter and 2.0mm in length.

Trial Locations (1)

02111

Tufts Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ocular Therapeutix, Inc.

INDUSTRY

lead

Tufts Medical Center

OTHER